ABT-089 is a drug developed by Abbott, which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic and neuroprotective effects, and animal studies suggested that it might be useful for the treatment of ADHD. Subsequent human trials have shown ABT-089 to both be effective for this application, and also to have particularly low tendency to cause side effects compared to other drugs in the class, making it a promising candidate for clinical development.
Study findings from University of Colorado, Institute for Behavioral Genetics broaden understanding of central nervous system.(Report)
Oct 25, 2010; Research findings, 'Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain,'...